Cargando…

Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo

BACKGROUND: It has been reported that cell inflammation pathways contribute to the development of prostaglandin E2 (PGE2)-inhibitor of DNA-binding protein-1 (ID1)-dependent radio-resistance in glioblastoma. Here, we proposed that inhibiting delta-6-desaturase (D6D) could block arachidonic acid synth...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jie, Liang, Huaxin, Sun, Meiyan, Zhang, Lei, Xu, Huijing, Liu, Wei, Li, Yan, Zhou, Yue, Li, Yingya, Li, Miao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289123/
https://www.ncbi.nlm.nih.gov/pubmed/30584371
http://dx.doi.org/10.2147/CMAR.S185601
_version_ 1783379927597318144
author Wang, Jie
Liang, Huaxin
Sun, Meiyan
Zhang, Lei
Xu, Huijing
Liu, Wei
Li, Yan
Zhou, Yue
Li, Yingya
Li, Miao
author_facet Wang, Jie
Liang, Huaxin
Sun, Meiyan
Zhang, Lei
Xu, Huijing
Liu, Wei
Li, Yan
Zhou, Yue
Li, Yingya
Li, Miao
author_sort Wang, Jie
collection PubMed
description BACKGROUND: It has been reported that cell inflammation pathways contribute to the development of prostaglandin E2 (PGE2)-inhibitor of DNA-binding protein-1 (ID1)-dependent radio-resistance in glioblastoma. Here, we proposed that inhibiting delta-6-desaturase (D6D) could block arachidonic acid synthesis and PGE2 production, thereby reversing PGE2-ID1-dependent radioresistance in glioblastoma cells and xenograft tumor models. MATERIALS AND METHODS: Two glioblastoma cell lines, namely, U-87 MG and LN-229, were used for the in vitro study. The combination effects of SC-26196 (a D6D inhibitor) and radiation were assessed by the MTS assay, colony formation assay, and cell apoptosis analysis. HPLC/MS analysis was performed to quantify the production of arachidonic acid and PGE2. For the in vivo study, 6-week-old nude mice, each bearing a U-87 MG xenograft tumor, were subjected to 4-week treatments of vehicle, SC-26196, radiation, or the combination of both. Tumor growth was monitored during the treatment, and the tumor tissues were collected at the end for further analysis. RESULTS: Treatment with SC-26196 significantly improved radiosensitivity in both glioblastoma cell lines in vitro, and radiosensitivity was associated with inhibited synthesis of arachidonic acid and PGE2. The combination of SC-26196 and radiation synergistically inhibited U-87 MG xenograft tumor growth, in association with the induction of tumor apoptosis and suppressed tumor proliferation. SC-26196 also inhibited arachidonic acid and PGE2 production in vivo and limited expression of ID1. CONCLUSION: These data suggested that the D6D inhibitor could reverse PGE2-ID1-dependent radioresistance in glioblastoma cells and xenograft tumor models by blocking the synthesis of arachidonic acid and PGE2. Although further investigation is required, the outcomes from this study may guide us in developing a potentially novel combination strategy for current glioblastoma therapy.
format Online
Article
Text
id pubmed-6289123
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62891232018-12-24 Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo Wang, Jie Liang, Huaxin Sun, Meiyan Zhang, Lei Xu, Huijing Liu, Wei Li, Yan Zhou, Yue Li, Yingya Li, Miao Cancer Manag Res Original Research BACKGROUND: It has been reported that cell inflammation pathways contribute to the development of prostaglandin E2 (PGE2)-inhibitor of DNA-binding protein-1 (ID1)-dependent radio-resistance in glioblastoma. Here, we proposed that inhibiting delta-6-desaturase (D6D) could block arachidonic acid synthesis and PGE2 production, thereby reversing PGE2-ID1-dependent radioresistance in glioblastoma cells and xenograft tumor models. MATERIALS AND METHODS: Two glioblastoma cell lines, namely, U-87 MG and LN-229, were used for the in vitro study. The combination effects of SC-26196 (a D6D inhibitor) and radiation were assessed by the MTS assay, colony formation assay, and cell apoptosis analysis. HPLC/MS analysis was performed to quantify the production of arachidonic acid and PGE2. For the in vivo study, 6-week-old nude mice, each bearing a U-87 MG xenograft tumor, were subjected to 4-week treatments of vehicle, SC-26196, radiation, or the combination of both. Tumor growth was monitored during the treatment, and the tumor tissues were collected at the end for further analysis. RESULTS: Treatment with SC-26196 significantly improved radiosensitivity in both glioblastoma cell lines in vitro, and radiosensitivity was associated with inhibited synthesis of arachidonic acid and PGE2. The combination of SC-26196 and radiation synergistically inhibited U-87 MG xenograft tumor growth, in association with the induction of tumor apoptosis and suppressed tumor proliferation. SC-26196 also inhibited arachidonic acid and PGE2 production in vivo and limited expression of ID1. CONCLUSION: These data suggested that the D6D inhibitor could reverse PGE2-ID1-dependent radioresistance in glioblastoma cells and xenograft tumor models by blocking the synthesis of arachidonic acid and PGE2. Although further investigation is required, the outcomes from this study may guide us in developing a potentially novel combination strategy for current glioblastoma therapy. Dove Medical Press 2018-12-07 /pmc/articles/PMC6289123/ /pubmed/30584371 http://dx.doi.org/10.2147/CMAR.S185601 Text en © 2018 Wang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Wang, Jie
Liang, Huaxin
Sun, Meiyan
Zhang, Lei
Xu, Huijing
Liu, Wei
Li, Yan
Zhou, Yue
Li, Yingya
Li, Miao
Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo
title Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo
title_full Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo
title_fullStr Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo
title_full_unstemmed Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo
title_short Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo
title_sort delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289123/
https://www.ncbi.nlm.nih.gov/pubmed/30584371
http://dx.doi.org/10.2147/CMAR.S185601
work_keys_str_mv AT wangjie delta6desaturaseinhibitorenhancesradiationtherapyinglioblastomainvitroandinvivo
AT lianghuaxin delta6desaturaseinhibitorenhancesradiationtherapyinglioblastomainvitroandinvivo
AT sunmeiyan delta6desaturaseinhibitorenhancesradiationtherapyinglioblastomainvitroandinvivo
AT zhanglei delta6desaturaseinhibitorenhancesradiationtherapyinglioblastomainvitroandinvivo
AT xuhuijing delta6desaturaseinhibitorenhancesradiationtherapyinglioblastomainvitroandinvivo
AT liuwei delta6desaturaseinhibitorenhancesradiationtherapyinglioblastomainvitroandinvivo
AT liyan delta6desaturaseinhibitorenhancesradiationtherapyinglioblastomainvitroandinvivo
AT zhouyue delta6desaturaseinhibitorenhancesradiationtherapyinglioblastomainvitroandinvivo
AT liyingya delta6desaturaseinhibitorenhancesradiationtherapyinglioblastomainvitroandinvivo
AT limiao delta6desaturaseinhibitorenhancesradiationtherapyinglioblastomainvitroandinvivo